What You Should Know:
– Verily and Janssen launches COVID-19 Immune Response Study that aims to collect detailed information about how the coronavirus affects the immune system immediately after someone tests positive for COVID-19.
Verily, an Alphabet company, is partnering with Janssen Research & Development LLC (Janssen) to launch a COVID-19 Immune Response Study as part of Verily’s Project Baseline. The study aims to collect detailed information about how the coronavirus affects the immune system immediately after someone tests positive for COVID-19. Project Baseline is an initiative to make it easy and engaging for people to contribute to the map of human health and participate in clinical research.
COVID-19 Immune Response Study
The prospective, exploratory study aims to enroll individuals confirmed positive for SARS-CoV-2 who will participate from home. The study will collect biological measurements, clinical and epidemiological data at the time of COVID-19 testing to characterize longitudinal molecular and/or immunological signatures associated with the progression of disease resulting from SARS-CoV-2 infection over 28 days.
“COVID-19 is impacting millions of people worldwide from all different backgrounds and health statuses,” said Jessica Mega, MD, MPH, Chief Medical and Scientific Officer, Verily. “We are pleased to partner with Janssen to conduct this important exploratory study which will focus on determining viral-induced immune response across different populations. We anticipate learnings from the study will help to better inform future treatment and prevention practices as the world continues to fight this devastating pandemic.”
Real-world data may be collected from participants spanning from up to two years prior to study participation, during active study visits, and up to two years following the last study assessment.
